Introduction {#s0005}
============

Oral cancer starts with an oral pre-invasive lesion (OPL) that progresses from hyperplasia through dysplasia, and finally develops into invasive oral squamous cell carcinoma (OSCC). Leukoplakia is the most predominant pre-invasive lesion [@bb0005], [@bb0010], [@bb0015], [@bb0020], however the ability to predict the malignant potential from histopathological data is limited. Moreover, the 5-year overall survival in OSCC has not substantially improved in recent decades [@bb0025], and early diagnosis and primary prevention remain the best approaches for OSCC management. To this end, the major challenge in early diagnosis is identifying pre-invasive lesions that are at high risk of malignant transformation [@bb0030], [@bb0035]. However, OSCC is frequently diagnosed in advanced stages, which negatively influences prognosis. The most important prognostic factors that determine mortality and morbidity in OSCC patients are lymph node involvement and locoregional recurrence.

The histopathological evaluation of oral cancers is often not sufficient to predict disease aggressiveness and clinical outcome [@bb0040]. Multiple genetic and epigenetic events occur before tissue changes are microscopically detectable. The number of acquired genetic alterations increases with disease advancement from squamous hyperplasia through dysplasia to invasive carcinoma [@bb0025]. It is known that copy number alterations (CNAs) ranging from a small number of specific genes to entire chromosomes are significantly associated with OSCC development and progression [@bb0045], [@bb0050]. These alterations are presumed to alter the expression level of single genes or gene clusters mapping within CNA regions [@bb0055]. Therefore, analyses that integrate CNA data with gene expression (GE) data may identify predictive DNA-based markers applicable in clinical prognosis [@bb0060].

Molecular profiles of oral cancers are largely influenced by the site of tumor development and associated etiological agents, implying divergent pathways for oral cancer development [@bb0065], [@bb0070], [@bb0075], [@bb0080], [@bb0085]. India is an interesting location to study the genomics of tobacco-associated OSCC, due to the fact that in India there is a high incidence of oral cancers associated with the abuse of smokeless tobacco, most of which are negative for human papilloma virus (HPV) [@bb0090].

This is the first comprehensive study combining genomic profiling and integrative analyses of HPV-negative gingivobuccal complex (GBC) leukoplakia and OSCC of different stages from a large set of Indian patients. We identified signatures associated with the progression of pre-invasive lesions to invasive OSCC and found candidate driver alterations unique to primary tumors with lymph node metastasis and related to patient survival.

Materials and Methods {#s0010}
=====================

Tissue Specimen Collection {#s0015}
--------------------------

The study was approved by the Institutional Local Ethics Committee of Tata Memorial Hospital (TMH) and Nair Hospital Dental College, Mumbai, India. Written informed consent was obtained from all the study participants. Paraffin blocks and frozen tissue samples of leukoplakia, neo-primary oral tumor tissues, and non-inflamed gingivobuccal mucosa tissues from clinically healthy individuals with no previous personal history of cancer were recruited from Nair Hospital and TMH, respectively. Patients received neither radiation nor chemotherapy before surgery. Histopathologically confirmed leukoplakia and tumor tissues were subjected to DNA--RNA extraction as detailed in Supplementary Information. Screening for the presence of HPV was done as described in [@bb0090]. Details regarding the numbers of samples used in the test and validation sets, as well as the clinicopathologic and demographic characteristics of patients, are provided in [Table 1](#t0005){ref-type="table"} and [Figure S1](#f0045){ref-type="graphic"}.

Array CGH and Gene Expression Profiling {#s0020}
---------------------------------------

Whole-genome copy number and gene expression profiling was performed on 2x105K CGH oligonucleotide arrays and Whole Human Genome Microarray 4x44K (Agilent Technologies, USA) respectively. Hybridization and detailed analysis are described in Supplementary Information. The raw aCGH data have been submitted to the Gene Expression Omnibus (GEO) with accession numbers [GSE85514](ncbi-geo:GSE85514){#ir0005} and [GSE23831](ncbi-geo:GSE23831){#ir0010} and accession numbers for GE raw data are GSE85195 and GSE23558.

Validation of Targets {#s0025}
---------------------

The copy number status of the targets was evaluated by fluorescence in situ hybridization (FISH/nuc ish). Immunohistochemical analysis (IHC) and quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) were performed for selected candidate genes found significantly deregulated. Detailed protocol and analysis is provided in Supplementary Information. Details regarding FISH probes, fluorescent TaqMan probes and antibodies used are listed in Tables S1, S2, S3.

Literature Mining {#s0030}
-----------------

We updated our existing literature-based list of genes related to oral cancer from 277 genes [@bb0050] to 562 genes (as of May 2015). The list (Table S4) includes genes that were previously found to be either differentially expressed or copy number altered in oral cancers. The purposes were 1) to place our new results in the context of previous knowledge and 2) to determine the novelty of any gene expression change or CNA that we would choose for targeted validation.

Results {#s0035}
=======

Clinicopathological and Demographic Characteristics of the Study Cohort {#s0040}
-----------------------------------------------------------------------

Clinicopathological and demographic characteristics of all 481 leukoplakia and OSCC patients, together with follow-up data, are summarized in [Tables 1](#t0005){ref-type="table"} and S5, while [Figure S1](#f0045){ref-type="graphic"} shows how many samples were used in each phase of the study. Most patients were smokeless tobacco users while many had mixed habits (\~35%) (chewing, bidi/cigarette smoking or consuming alcohol) and were negative for high-risk HPV [@bb0090]. The histopathology of the leukoplakia samples was either hyperplastic (89 samples) or mild dysplastic (11 samples) and 50% of the lesions analyzed for aCGH and GE study either transformed to OSCC or recurred after primary treatment. One hundred forty-nine patients (\~65%) had advanced-stage OSCC and 82 patients (\~35%) had early-stage OSCC. Approximately 60% cases were negative for lymph node metastasis.

Genome-Wide copy Number Alterations {#s0045}
-----------------------------------

Genome-wide analysis of CNA was carried out in 24 leukoplakia, 32 early-stage OSCC, and 59 advanced-stage OSCC cases and revealed recurrent focal regions of amplification and deletion ([Figures 1](#f0005){ref-type="fig"} and [S2](#f0050){ref-type="graphic"}). We identified 19 alterations in leukoplakia, 32 alterations in early-stage OSCCs and 69 alterations in advanced-stage OSCCs (Table S6). The 10 most frequently amplified regions were 11q13.1 (70% of all patients), 8q24.3 (69%), 11p15.5 (60%), 1p36.33 (59%), 9q34.3 (59%), 8q24.21 (55%), 7q22.1 (54%), 7q11.23 (53%), 16p13.3 (53%) and 3q27.2 (52%). The 10 most frequently deleted regions were 8p23.2 (66% of all patients), 8p11.22 (65%), 3p14.2 (56%), 3p21.1 (54%), 8p22 (54%), 3p11.1 (53%), 3p22.3 (53%), 3p26.3 (53%), 8p23.1 (51%) and 15q11.1 (40%). Previous reports have proposed amplifications in 3q26-qter, 8q24-qter, and 11q13.2-q13.4 to be common in high grade dysplasia, and amplifications in 3q, 7p, 8q, 11q, together with deletions in 3p and 8p to be most common in OSCCs [@bb0095].

### CNAs associated with disease progression {#s0050}

Alterations associated with disease progression were identified by comparison between the following groups: 1) leukoplakia vs. early-stage OSCC, 2) leukoplakia vs. advanced-stage OSCC, and 3) early-stage OSCC vs. advanced-stage OSCC ([Figure S2](#f0050){ref-type="graphic"}). Three amplified regions (4q13.2, 6p21.32, 8q24.3) and four deleted regions (8p23.1, 8p11.22, 14q11.2, 15q11.1) are common among the leukoplakia, early-stage OSCC, and advanced-stage OSCC samples ([Figures 1](#f0005){ref-type="fig"} and [S2](#f0050){ref-type="graphic"}), suggesting their involvement in disease progression. Interestingly, the amplification of 8q24.3 (harboring the candidate genes *FBXL6, GPR172A, PTP4A3*) was found in almost 60% of the analyzed leukoplakia cases and also in almost 70% of the tumors (Table S6).

We validated the 8q24.3 amplification by nuc ish using a disjoint validation set of 108 leukoplakia and 185 OSCC samples ([Figure 2](#f0010){ref-type="fig"}*A* and [Table 1](#t0005){ref-type="table"}). The 8q24.3 locus-specific probe and a centromere 8 probe hybridized to their target loci and showed no cross reactivity ([Figure 2](#f0010){ref-type="fig"}*A*). The percentage of cells with 8q24.3 amplification increased as disease progressed from leukoplakia to OSCC, and the amplification was associated with disease progression (*P* \<0.001) ([Figure 3](#f0015){ref-type="fig"}*A*). Almost 95% of the advanced-stage OSCC samples used for validation had a weak amplification of 8q24.3 in more than 40% of the tumor cells ([Figure 3](#f0015){ref-type="fig"}*B*). Moreover, this amplification was significantly associated with tumor grade (*P =*.046) and lymph node metastasis (*P =*. 0.007). The strong amplification of 8q24.3 in leukoplakia and tumors was only present in 5--20% of cells ([Figure 3](#f0015){ref-type="fig"}*C*). Our validation results confirm that 8q24.3 amplification is an important early event associated with OSCC progression.

### CNAs associated with clinical outcome {#s0055}

Chromosomal alterations were also analyzed for their associations with clinicopathologic parameters, including nodal status, grade, and survival. We identified 64 recurrent chromosomal alterations in lymph node metastasis-negative OSCCs and 46 recurrent alterations in lymph node metastasis-positive OSCCs (q-value \<0.25, [Figure S3](#f0055){ref-type="graphic"}). In addition, we found 13 alterations unique to the primary tumors that metastasized to the nodes ([Figure S2](#f0050){ref-type="graphic"}C and D), including amplifications of 8p23.1, 8q24.21 (harboring the candidate gene *MYC*), 11q22.1 (*MMPs, BIRC2, BIRC3*), and deletions of 2q23.3, 3p26.3 (*CHL1*), 3p12.2, 4q21.3, 7q31.1, 8p23.2 (*CSMD1*), 9p12, 11q22.3 (*ATM, H2AFX*), as well as 18q12.1. We hypothesize that these alterations are potential predictive biomarkers of lymph node metastasis. According to previous studies, the amplification of 8q24.21 and the deletion of 3p26.3 are associated with metastasis, invasion, and therapy resistance [@bb0100], [@bb0105].

We found 25 CNAs associated with recurrence-free survival and 26 CNAs associated with disease specific survival (q-value \<0.25, [Table 2](#t0010){ref-type="table"}). For example, the amplifications of 1p36.33, 11q13.3, 11q22.1 and 16p11.2 were associated with poor clinical outcome, whereas the amplification of 22q11.21 was associated with better survival. Additionally, a poor clinical outcome was also associated with the deletions of 2p11.2, 3p14.2, 4q13.2, 9p23 and 11q22.3. Kaplan--Meier survival curves for 1p36.33 and 11q22.1 are shown in [Figure 4](#f0020){ref-type="fig"}*A*. We validated the amplification of 1p36.33 by nuc ish ([Figure 2](#f0010){ref-type="fig"}*B*), and we confirmed that the amplification of 1p36.33 is associated with poor survival in an independent OSCC cohort ([Figure 4](#f0020){ref-type="fig"}*B*). Moreover, we found a strong association between the amplification of 1p36.33 and lymph node metastasis (*P* \< .001).

Gene Expression and Integrative Analyses {#s0060}
----------------------------------------

Transcriptome-wide analysis was performed on 6 buccal mucosa normal tissues, 15 leukoplakia, 27 early-stage OSCC, and 34 advanced-stage OSCC. Principal component analysis of 3805 differentially expressed genes (log fold change of 2 and q-value ≤0.01) revealed two separate clusters of normal and OSCC samples, while the leukoplakia samples displayed changes overlapping with both these groups ([Figure S4](#f0060){ref-type="graphic"}). We identified 849 genes differentially expressed (395 up-regulated and 454 down-regulated) in leukoplakia, 1813 (805 up-regulated and 1008 down-regulated) in early-stage OSCC, and 1924 (798 up-regulated and 1056 down-regulated) in advanced-stage OSCC ([Figure S5](#f0065){ref-type="graphic"}). Up-regulation of *NELL2, MFAP5, CA2, FLRT3, HOXC9, CDH16, LRP12, PTPRZ1, TNNT1, WDR66, NEXN, EGR2, HOXC13, E2F7, ECT2*, *EIF5A2* and down-regulation of *KRT19, DERL3, CD177, PSCA, FAM3B, ALOX12, MUC20, CXCL13, KRT4, KRT3, CD19, KRT81, CLDN7, FCRL5, POU2AF1, CD79A, TMPRSS2, MAL, TNFRSF17, FCN1, PNOC, CXCL17, CEACAM1, FUT6, CLCA4, PITX1, DACT2, MEI1, GPX3* were observed in all three groups, revealing their role in disease progression from pre-invasive to cancerous lesions. A higher number of genes were dysregulated in OSCC compared to leukoplakia, including *CXCL10, MMP10, INHBA, GBP5, CXCL11, MMP3, FST, BATF2, SPP1, SH2D5, CXCL9, IFIT3, SERPINE1, GALNT6, FOXL2, PDPN, ITGA3, VEGFC, STAT1, LY6K, KLF7, SOX9* and *CD274.* Among all the differentially expressed genes identified in this study, 61 have been previously reported to be involved in leukoplakia and 188 in oral or head and neck cancers, including *ECT2, INHBA, SERPINE1, GBP5, MMP10, MMP3, LY6K, SPP1, PDL1, PTHLH, KRT4, KRT76* and *MAL*[@bb0050], [@bb0110], [@bb0115], [@bb0120], [@bb0125], [@bb0130]. The novel oral cancer driving genes identified here include *DERL3, EIF5A2, HOXC9, HOXC13, MFAP5, NELL2, CD274, DHRS2, FST* and *GPX3*. The top dysregulated genes in leukoplakia and OSCC are represented in [Figure 5](#f0025){ref-type="fig"} and listed in Table S7.

### Integrative analysis of gene expression and CNAs {#s0065}

We integrated the GE and CNA datasets to identify genes whose expression and copy number status were correlated. We found 3q26.31, 6p21.1, 7p11.2, 8q24.21, 8q24.3, 9p24.1, 11q13.3, 12q13.2, 16q24.2 and 17p13.1 as chromosomal hotspots for copy number-dependent gene overexpression, while 1q44, 2q34, 3p26.3, 3p21.1, 10p11.21, 11q22.3, 17p13.1 and 21q21.3 were identified as regions of copy number-dependent gene down-regulation ([Table 3](#t0015){ref-type="table"}). In particular, 3q26.31 and 12q13.2, spanning the genes *ECT2, EIF5A2, HOXC9, HOXC13* and *MUCL1*, showed a strong correlation between copy number amplifications and gene over-expression. The deletion of 11q22.33 was correlated with a few genes with significant copy number-dependent underexpression, including *CRYAB, POU2AF1, EXPH5, MPZL2* and *ARHGAP32*. The opposite direction of expression change (amplification of down-regulated genes and deletion of up-regulated genes) was observed for a few genes, including *MMP3, MMP10, FEZ1, CTSC, CHEK1, PANX1* and *PAFAH1B2*. Interestingly, 16p11.2, 17p13.1 and 22q11.23 were significantly amplified, however, the majority of the genes located in these three regions were down-regulated, e.g., *CD19, GDPD3, NUPR1, SPN, CLDN7* and *DERL3* ([Table 3](#t0015){ref-type="table"}), potentially a consequence of epigenetic regulation.

### Validation of dysregulated transcripts {#s0070}

To confirm the results of the GE analysis, real-time qRT-PCR (TaqMan assays) was performed in 32 normal, 37 leukoplakia, and 138 OSCC samples. We selected 10 genes for validation based on either novelty or on published studies implicating these genes in OSCC development (Table S4): seven up-regulated genes *DVL1, EIF5A2, FUS, HOXC9, INHBA, LY6K,* and *MFAP5*, two down-regulated genes *DERL3* and *MAL*, and the unchanged gene *SLC4A1AP*, along with *RNA18S5* as endogenous control. All the validation targets that were found to be differentially expressed in the GE analysis were confirmed to display significant differences in expression between normal, leukoplakia, and tumors ([Figure 6](#f0030){ref-type="fig"}), and no significant difference was found in the expression of the unchanged gene *SLC4A1AP.* Specifically, *HOXC9, MFAP5,* and *INHBA* showed very high expression changes in leukoplakia, early and advanced tumors versus normal (*P*\<.01), while *EIF5A2* and *LY6K* were significantly overexpressed only in early and advanced-stage OSCCs (*P*\<.0001 and *P =*.03, respectively). The log~2~ fold change in expression of *DVL1* and *FUS* was approximately 1 across the three groups, consistent with the microarray data.

We analyzed the associations between the validated target genes and clinicopathologic parameters ([Table 4](#t0020){ref-type="table"}). Most targets (*EIF5A2, HOXC9, MFAP5, LY6K, INHBA* and *DVL1*) showed a positive correlation between their expression changes and OSCC progression from pre-invasive lesions to cancer. The expressions of *DERL3* and *MAL*, which are down-regulated, were negatively correlated with disease progression. *EIF5A2, HOXC9, INHBA,* and *MFAP5* were associated with disease advancement from early-stage OSCC to advanced-stage OSCC, and *EIF5A2, HOXC9, INHBA, FUS* and *DVL1* were significantly associated with lymph node metastasis. IHC was performed to validate the protein overexpression of EIF5A2, ECT2, HOXC9, HOXC13, MFAP5, and NELL2. IHC analysis revealed strong protein expression of all the six targets in leukoplakia (n = 108) and OSCC (n = 185) versus normal (n = 77) ([Figure 7](#f0035){ref-type="fig"}). Further analyses reinforced the associations of these markers with disease progression, except *NELL2* ([Figure S6](#f0070){ref-type="graphic"} and Table S8).

Pathway Analyses {#s0075}
----------------

To interpret the association of dysregulated genes with biological processes, we used the PANTHER (Protein ANalysis THrough Evolutionary Relationships) classification system [@bb0135], [@bb0140] ([Figure S7](#f0075){ref-type="graphic"}). Both leukoplakia and OSCC samples shared a large number of dysregulated processes. However, we identified a higher number of OSCC-related genes as part of dysregulated pathways as compared to genes related to pre-invasive lesions. Among them, we note genes associated with apoptotic processes (*FADD, BAX, BAK1, CASP7, INHBA, BIRC5*), developmental processes (*HOXC9, HOXC13, NELL2, CD274, ETS, STAT1*), biological regulation (*BATF, HOXC9, TERC*), and metabolic processes (*RAD51, HOXC13, E2F1, HOXB6, CDK1*). The top representative biological processes significantly altered in leukoplakia and OSCC are listed in [Table 5](#t0025){ref-type="table"}.

Discussion {#s0080}
==========

We have presented the first comprehensive analysis of genomic and transcriptomic profiles of a large set of tobacco-associated, HPV-negative gingivobuccal leukoplakia and OSCC patients from India. Our main goals were threefold: 1) to identify novel driver events associated with the transformation of pre-invasive lesions to high risk malignant OSCCs, as well as with patient survival; 2) to identify unique driver alterations found in primary tumors with lymph node metastasis; and 3) to identify driver genes with correlated CNA and gene expression profiles. Therefore, our study contributes to a genetic progression model of oral carcinogenesis ([Figure 8](#f0040){ref-type="fig"}).

The CNA landscape of gingivobuccal cancers is dominated by amplifications of the chromosomal regions 1p36.33, 3q26.31, 6p21.32, 7p11.2, 8q24.21, 8q24.3, 9q34.3, 11q13.1, 11q13.3, 11q22.1, 12q13.2, 16p11.2, and deletions of 3p21.1, 3p14.2, 4q21.3, 8p23.2, 8p11.22, 9p23, 9p21.3, 17p13.1. The amplifications of 3q, 7p, 8q, 9q, 11q, and 12q, as well as the deletions of 3p, 4q, 8p, and 9p were reported at least three times among 12 aCGH studies on primary OSCC tumors [@bb0095], with amplifications of 3q26, 11q13 and 11q22.2 being the most reported CNAs in advanced-stage OSCCs [@bb0045], [@bb0145], [@bb0150]. An extensive review by Gollin outlines established associations of most of these alterations in HNSCC [@bb0155]. In our data, at the whole-arm level, the amplification of 8q is the most common amplification associated with OSCC progression. At the sub-band level, the amplification of 8q24.3 was observed in 58% of the leukoplakia samples, as well as in 69% of the OSCC samples, while the region 8q24.21 was amplified in 55% of the OSCC samples. *PTK2, LY6K,* and *MYC* are prominent candidate oncogenes on 8q [@bb0050], [@bb0160], [@bb0165], [@bb0170]. In addition, we observed deletions of multiple regions on 3p (3p26.3, 3p22.3, 3p21.1, 3p14.2, 3p11.1) and 8p (8p23.2, 8p23.1, 8p22, 8p11.22) with high frequency (\>52% in OSCCs), in line with literature reports in oral pre-invasive lesions [@bb0175], [@bb0180]. These alterations can therefore be considered as important events associated with OSCC progression [@bb0180].

We observed strong correlations between gene expression and amplifications at 3q26.31 (including the genes *ECT2, EIF5A2, KLHL6, GPR160*) and 12q13.2 (*HOXC9, HOXC13, ERBB3, MUCL1*) in both leukoplakia and OSCC. Amplifications at 9p24.1 (*CD274*), 11q13.3 (*ANO1*), and 7p11.2 (*EGFR*) were only identified in OSCCs, indicating their role in disease advancement, rather than their appearance at pre-invasive stages. Additionally, *CD274* and its ligand PD1 are important targets of immunotherapy in various cancers, including OSCC [@bb0185], [@bb0190], [@bb0195], [@bb0200].

A second hotspot for CNA-dependent gene over-expression was observed on 3q26.31, with *ECT2* and the oncogene *EIF5A2* over-expressed. Overexpression of *EIF5A2* has not been previously reported in leukoplakia or OSCC, even though it has been proposed as a prognosis biomarker and potential therapeutic target for various other human tumors [@bb0205], [@bb0210], [@bb0215], [@bb0220]. *ECT2* has been previously found to be overexpressed in oral cancers [@bb0110], and also be involved in metastasis and angiogenesis of solid tumors [@bb0215], [@bb0225], [@bb0230], [@bb0235].

A third interval of interest for amplifications and gene overexpression is 12q13.2, comprising of *HOXC9* and *HOXC13*, genes associated with disease progression in OSCC. The *HOX* transcriptional regulators family is involved in pattern formation and organogenesis during embryo development [@bb0240] and potentially in the maintenance and regulation of cancer stem cells [@bb0245]. In particular, *HOXC9* has been linked with cell cycle exit and cell invasion in breast cancer and neuroblastoma [@bb0240], [@bb0250], [@bb0255], [@bb0260], and *HOXC13* plays an important role in maintaining skin homeostasis and in regulating the transcription of cytokeratins genes [@bb0265], [@bb0270]. Kasiri et al. [@bb0275] and Cantile et al. [@bb0280] showed that *HOXC13* is a key player in tumor cell growth and viability in various human cancers.

Pathare et al. [@bb0285] and Bhattacharya et al. [@bb0290] demonstrated that specific CNAs are associated with lymph node metastasis. Here, the most frequent such alteration, specific to the lymph node metastatic tumors, was the amplified region 8q24.21 (57%), which includes the gene *MYC*, whose over-expression is postulated to activate various hallmarks of cancer, such as metastasis, invasion, and therapy resistance [@bb0100], [@bb0295]. A highly recurrent deletion identified was 3p26.3 (57%), including the gene *CHL1*, alteration previously reported as a predictor of survival and lymph node metastasis in OSCC, along with loss of 3p14.2 (*FHIT*) [@bb0105], [@bb0300]. The deletion of 8p23.2 was the most frequent in our study (68%). Genes in this region have been reported to be involved in lung, head and neck, breast, and skin cancers [@bb0305], but further studies are required to delineate its functional role in OSCC progression.

We separately analyzed early-stage and advanced-stage OSCCs to identify distinguishable CNAs with respect to recurrence and survival. For the first time, we report a recurrent amplification on 1p36.33 as significantly associated with clinical outcomes. Literature evidence supports that genes located on 1p, including *JUN* (1p32--31), *TP73* (1p36.3), *CASP9* (1p36.21), and *NRAS* (1p13.2), are important in the initiation and progression of several cancer types [@bb0310], [@bb0315]. Genes of interest on the 1p36.33 amplicon include *MXRA8* and *DVL1*. Here, we report the copy number dependent up-regulation of *MXRA8*, previously shown to function in tumor stroma by aiding the recovery of angiogenesis in capillaries [@bb0320], [@bb0325]. *DVL1* belongs to the Wnt signaling pathway known to be involved in growth, progression, and metastasis of various cancer types [@bb0330].

Additionally, we report copy number independent up-regulation of *INHBA, MFAP5* and *NELL2* in both leukoplakia and OSCC samples. *MFAP5* is a secretory stromal protein overexpressed in leukoplakia and OSCC, possibly playing a role in malignant transformation and as a potential serum biomarker of cancer progression. Reports on ovarian cancer suggest that *MFAP5* promotes tumor cell survival and angiogenesis through α~5~β~3~ integrin-mediated signaling [@bb0335], [@bb0340], [@bb0345]. We identified few genes in copy number-altered regions that had a significant expression change in the direction opposite to what would be expected (e.g., a down-regulated gene in an amplified region), possibly following epigenetic regulation. One example is the down-regulation of *DERL3*, located at the 22q11.23 amplicon. Further studies are needed to confirm the significance of the *DERL3* in oral tumorigenesis and to understand its gene regulation.

In sum, our study identifies CNAs and gene expression changes related to oral cancer progression. Alterations shared between leukoplakia and OSCC can be considered as important early events that are essential for initial cell transformation and progression. Integrative analysis of CNA and gene expression allows us to identify various novel drivers in oral cancer pathogenesis.

The following are the supplementary data related to this articleSupplementary Figure CaptionImage 1Figure S1.The set of all samples (normal, leukoplakia and OSCC) used for array CGH (aCGH), gene expression (GE) and validation analyses (qRT-PCR, FISH and IHC). The numbers of samples are displayed in brackets.Figure S1Figure S2.Copy number Amplifications (A and C) and Deletions (B and D) identified in leukoplakia, early-stage OSCC and advanced-stage OSCC (A and B), as well as in node negative (N0) and node positive (N+, C and D) samples.Figure S2Figure S3.All amplifications (a) and deletions (b) inferred by GISTIC 2.0 in node negative (N0, A) and node positive (N+, B) OSCC samples. Each aberration is assigned a G-score (left axis) by GISTIC 2.0, which considers the amplitude of the aberration, as well as its occurrence across samples.Figure S3Figure S4.PCA plot of the 82 samples analyzed, consisting of 34 advanced and 27 early cancerous lesions, 15 leukoplakia lesions and 6 buccal tissues, acting as controls. The PCA was performed based on the union of all genes differentially expressed (3805 genes), when comparing any two of the four categories of samples plotted here (fold change thresholds of 2 and q-value threshold of 0.01). *P*-values were corrected for multiple testing using the Benjamini-Hochberg procedure. The percent variance of each of the two components is represented in brackets.Figure S4Figure S5.Venn diagrams depicting the numbers of common and unique differentially expressed genes in leukoplakia (orange), early-stage OSCC (blue), and advanced-stage OSCC (pink).Figure S5Figure S6.Correlation between protein overexpression and oral cancer progression. A) Significant increase in cytoplasmic and nuclear HOXC9 in leukoplakia and OSCC, as compared to the normal buccal mucosa tissue. B) Significant cytoplasmic overexpression of EIF5A2, as compared to the normal tissue, was more prominent in leukoplakia than in OSCC. C) Increase in the cytoplasmic expression of NELL2 in both leukoplakia and OSCC, however not statistically significant. D) Cytoplasmic overexpression of ECT2 in both leukoplakia and OSCC, and nuclear overexpression of ECT2 only in OSCC. E) Very high overexpression of MFAP5 in the matrix in both leukoplakia and OSCC. F) Increased progressive cytoplasmic expression of HOXC13 between normal tissue, leukoplakia, and OSCC. In all plots, the Y axis represents the H score for protein expression, computed as described in Supplementary Information. *P*-values (*P*) were calculated using a Spearman correlation analysis.Figure S6Figure S7.Biological processes altered in leukoplakia and OSCC. The plots represent the number of genes associated with dysregulated biological processes, built using the tool PANTHER. "Total \# Genes" represents the total number of deregulated genes in either leukoplakia or OSCC, and "Total \# process hits" represents the total number of biological process in the PANTHER library.Figure S7Figure S8.Enumeration of nuc ish signals. 8q24.3 locus probe (red)/chr 8 centromere (CEP) (green).Figure S8Supplementary Table CaptionTable S1: Agilent SureFISH probe details.Table S2: Taqman assay IDs of genes validated by qRT-PCR.Table S3: Antibodies used for immunochemistry (IHC) analysis.Table S4: Literature-based list of genes related to oral cancer.Table S5: Detailed clinicopathological and demographic characteristics of the (A) leukoplakia and (B) OSCC samples used for the aCGH and gene expression study.Table S6: Significantly recurrent CNAs identified across the (A) leukoplakia, (B) OSCC, (C) early-stage OSCC, (D) advanced-stage OSCC, (E) node negative, and (F) node positive samples.Table S7: Top 50 (A) up-regulated and (B) down-regulated genes in leukoplakia and OSCC, ordered by their log 2 fold change (LFC).Table S8: Correlation of IHC validation targets with clinicopathological parameters.Image 2
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![All amplifications (a) and deletions (b) inferred by GISTIC 2.0 in leukoplakia (A), early-stage OSCC (B), and advanced-stage OSCC (C) samples. Each alteration is assigned a G-score (left axis) by GISTIC 2.0, which considers the amplitude of the alteration, as well as its occurrence across samples.](gr1){#f0005}

![Nuc ish (FISH) for validating the amplifications of the regions 8q24.3 and 1p36.33. A) nuc ish for 8q24.3 locus in leukoplakia (b) and OSCC (c). B) nuc ish for 1p36.33 locus with weak amplification (b) and strong amplification (c) in OSCC. The specificities of the 8q24.3 locus probe (red)/chr 8 centromere (CEP) (green) and 1p36.33 (red) locus probe/chr 1 centromere (CEP) (green) were confirmed on the metaphase spreads as represented in A(a) and B(a). In all cases, the magnification was 630X.](gr2){#f0010}

![Correlation between 8q24.3 amplification and oral cancer progression. A) Percentage of cells with 8q24.3 weak amplification across different groups, correlated with disease progression (*P*-value calculated using Spearman correlation). B) and C) The increased percentage of tumor cells with 8q24.3 amplification in leukoplakia and OSCC.](gr3){#f0015}

![Kaplan--Meier plots of disease specific patient survival for selected chromosomal alterations based on aCGH analysis (A, 1p36.33 and 11q22.1) and nuc ish validation experiments (B, 1p36.33). Survival in months (X axis) is plotted against the fraction of patients alive (Y axis).](gr4){#f0020}

![Heatmap of the top 20 differentially expressed genes in leukoplakia and OSCC. A) Differentially expressed genes in early-stage OSCC (pink) and advanced-stage OSCC (magenta) when compared to normal (green). B) Differentially expressed genes in leukoplakia (chartreuse) when compared to normal (green). Blue genes are up-regulated, while down-regulation is represented in red. All expression values were scaled across samples.](gr5){#f0025}

![qRT-PCR expression changes of the 10 target genes (2 down-regulated, 7 up-regulated and 1 unchanged) in normal, leukoplakia and early and advanced-stage OSCC samples. The *P*-value (*P*) was calculated using the Spearman correlation test.](gr6){#f0030}

![IHC analysis for target validation in normal, leukoplakia, and OSCC samples. NELL2 showed cytoplasmic staining, EIF5A2, ECT2, HOXC9, HOXC13 showed cytoplasmic and nuclear expression, while MFAP5 was localized predominantly into the matrix. Respective isotype controls for all the cases had no staining (images not shown). The rightmost panel shows differential localization of each marker. The magnification was 100X for the leftmost three panels, and 200X for the rightmost panel.](gr7){#f0035}

![Summary of the predictive genomic and transcriptomic signatures associated with gingivobuccal cancer progression from pre-invasive lesions (leukoplakia) to cancer and lymph node metastasis. (\*) represents alterations associated with disease specific survival in OSCC patients. Amp: Amplification (red); Del: Deletion (blue); Up: genes up-regulated (red), Down: genes down-regulated (blue).](gr8){#f0040}

###### 

The Clinicopathologic and Demographic Characteristic of the Study Patients.

Table 1

  Patient Characteristics                        Total Study Samples   aCGH & GE Study (n = 121)\#   qRT-PCR (n = 207)\#       IHC & FISH (n = 370)\#                              
  ---------------------------------------------- --------------------- ----------------------------- ------------------------- ------------------------ ------------- ------------ -------------
                                                 n = 481               aCGH: n = 24 GE: n = 15       aCGH: n = 91 GE: n = 61   n = 37                   n = 138       n = 108      n = 185
  Age at diagnosis                                                                                                                                                                 
   Median age                                    49                    42                            50                        41                       50            44           50
   Range (IQR)\*                                 40--59                38--50                        43--61                    33--53                   42--59        32--57       42--60
  Gender                                                                                                                                                                           
   Male                                          299 (76.3%)           21 (87.5%)                    70 (76.9%)                33 (89.2%)               102 (75.6%)   96 (90.6%)   140 (75.7%)
   Female                                        93 (23.7%)            3 (12.5%)                     21 (23.1%)                4 (10.8%)                33 (24.4%)    10 (9.4%)    45 (24.3%)
  Pathological stage                                                                                                                                                               
   Stage 1 and 2 (Early stage OSCC)              82 (35.5%)            NA                            32 (35.2%)                NA                       56 (41.5%)    NA           67 (36.2%)
   Stage 3 and 4 (Advanced stage OSCC)           149 (64.5%)           NA                            59 (64.8%)                NA                       79 (58.5%)    NA           118 (63.8%)
  Pathological T classification                                                                                                                                                    
   T1                                            31 (13.4%)            NA                            7 (7.7%)                  NA                       25 (18.5%)    NA           24 (13%)
   T2                                            100 (43.3%)           NA                            40 (44%)                  NA                       64 (47.4%)    NA           80 (43.2%)
   T3                                            10 (4.3%)             NA                            4 (4.4%)                  NA                       4 (3%)        NA           8 (4.3%)
   T4                                            90 (39%)              NA                            40 (44%)                  NA                       42 (31.1%)    NA           73 (39.5%)
  Pathological cervical lymph node involvement                                                                                                                                     
   Node negative (N0)                            133 (57.6%)           NA                            55 (60.4%)                NA                       79 (58.5%)    NA           112 (60.5%)
   Node positive (N+)                            98 (42.4%)            NA                            36 (39.6%)                NA                       56 (41.5%)    NA           73 (39.5%)
  Pathological grade                                                                                                                                                               
   Well                                          27 (7.9%)             NA                            8 (8.8%)                  NA                       12 (8.9%)     NA           23 (12.5%)
   Moderate                                      139 (40.9%)           NA                            55 (60.4%)                NA                       87 (64.4%)    NA           106 (57.6%)
   Poor                                          64 (18.8%)            NA                            28 (30.8%)                NA                       36 (26.7%)    NA           55 (29.9%)
   Hyperplasia                                   89 (26.2%)            21 (87.5%)                    NA                        31 (86.1%)               NA            80 (80.8%)   NA
   Mild dysplasia                                11 (3.2%)             3 (12.5%)                     NA                        3 (8.3%)                 NA            9 (9.1%)     NA
   Moderate dysplasia                            8 (2.4%)              NA                            NA                        2 (5.6%)                 NA            8 (8.1%)     NA
   Severe Dysplasia                              2 (0.6%)              NA                            NA                        NA                       NA            2 (2%)       NA
  Habit profile                                                                                                                                                                    
   No Habit                                      9 (3.1%)              9 (45%)                       NA                        NA                       3 (2.6%)      NA           8 (5.3%)
   Exclusive tobacco users                       157 (54.5%)           3 (15%)                       63 (77.8%)                13 (41.9%)               79 (70%)      30 (33%)     98 (64.5%)
   Exclusive smoker                              18 (6.3%)             NA                            2 (2.5%)                  5 (16.2%)                2 (2%)        12 (13.2%)   4 (2.6%)
   Exclusive alcohol drinker                     1 (0.3%)              NA                            NA                        NA                       1 (0.8%)      NA           1 (0.7%)
   Mixed habit\*\*                               103 (35.8%)           8 (40%)                       16 (19.8%)                13 (41.9%)               28 (24.7%)    49 (53.8%)   41 (27%)

\# Represents total number of samples, including Buccal Mucosa (BM) Normals: n = 6 (GE), n = 32 (qRT-PCR) and n = 77 (IHC); all samples belonged to the gingivobuccal complex region of the oral cavity; T: Tumor classification based on size; N: Tumor classification based on lymph node metastasis; \* IQR: Inter quartile range; \*\*Mixed Habit: Tobacco chewing along with bidi/cigarette smoking and/or alcohol users.

###### 

Univariate Cox Proportional Hazards Regression Analysis of Single Predictors for Recurrence-Free and Disease Specific Survival.

Table 2

  Cytoband    Alteration      Disease Specific Survival   Recurrence-Free Survival            
  ----------- --------------- --------------------------- -------------------------- -------- ---------
  1p36.33\*   Amplification   0.0327                      1.0292                     0.013    0.9185
  1q23.2      Amplification   0.0269                      0.8763                     0.0934   0.574
  3q27.2      Amplification   0.2467                      0.436                      0.2171   0.3823
  11q13.3     Amplification   0.1232                      0.4237                     0.2142   0.2804
  16p13.3     Amplification   0.0655                      0.6641                     0.0658   0.5375
  16p11.2     Amplification   0.0497                      0.8665                     0.0549   0.6726
  16q12.2     Amplification   0.0607                      0.6662                     0.0308   0.6497
  2p11.2      Deletion        0.0473                      1.0051                     0.0844   0.777
  2q22.1      Deletion        0.0147                      1.0214                     0.0623   0.6329
  2q34        Deletion        0.0644                      0.7772                     0.0281   0.745
  3p14.2      Deletion        0.1976                      0.5665                     0.2202   0.4236
  4q13.2      Deletion        0.0582                      0.8036                     0.1775   0.4836
  4q22.1      Deletion        0.0998                      0.7098                     0.2113   0.4591
  9p23        Deletion        0.0969                      0.711                      0.1339   0.5327
  11q22.3     Deletion        0.0829                      0.7902                     0.099    0.6467
  6p21.1      Amplification   0.2198                      0.4606                     \-       \-
  11q22.1     Amplification   0.1543                      0.5204                     \-       \-
  18p11.31    Amplification   0.2227                      0.5128                     \-       \-
  22q11.21    Amplification   0.1832                      −0.6038                    \-       \-
  1q31.3      Deletion        0.2371                      0.5055                     \-       \-
  3p11.1      Deletion        0.0809                      0.7957                     \-       \-
  4q13.2      Deletion        0.09                        0.7457                     \-       \-
  5p14.3      Deletion        0.112                       0.7583                     \-       \-
  7q31.1      Deletion        0.1624                      0.598                      \-       \-
  13q21.32    Deletion        0.2166                      0.5221                     \-       \-
  21q21.3     Deletion        0.1385                      0.6243                     \-       \-
  2q37.3      Amplification   \-                          \-                         0.2185   0.3978
  5p15.33     Amplification   \-                          \-                         0.223    0.3284
  11p15.5     Amplification   \-                          \-                         0.1793   0.4287
  13q21.33    Amplification   \-                          \-                         0.2436   −0.7795
  16q21       Amplification   \-                          \-                         0.1975   0.4048
  19p13.3     Amplification   \-                          \-                         0.1465   0.3602
  22q11.23    Amplification   \-                          \-                         0.1986   −0.4272
  9p21.3      Deletion        \-                          \-                         0.2007   0.4494
  14q11.2     Deletion        \-                          \-                         0.1116   0.5358
  17p13.1     Deletion        \-                          \-                         0.0346   0.7927

BH: Benjamini-Hochberg multiple testing correction method; CPH coef.: Cox Proportional Hazard coefficient. A positive regression coefficient means that the hazard is higher, thus the prognosis is worse; \* Targets selected for validation; − represents not applicable.

###### 

Associations Between DNA Copy Number Alterations and Differentially Expressed Transcripts in Leukoplakia and OSCC.

Table 3

![](t1)

DE: Differential expression; Red font indicates amplified loci or up-regulated genes, and Blue font indicates deleted loci or down-regulated genes. The majority of genes showed consistent changes on both the DNA and the RNA levels, and are depicted here in black font (up-regulated genes in amplified regions and down-regulated genes in deleted regions). Few genes showed opposite direction expression changes and are colored respectively (genes in blue font were down-regulated, but located in amplified regions, while genes in red font were up-regulated, but located in deleted regions). \* Targets selected for validation.

###### 

Correlation of qRT-PCR Validation Targets with clinicopathological parameters.

Table 4

  Targets (Genes) →                         *EIF5A2* ↑   *HOXC9 ↑*            *INHBA ↑*            *MFAP5 ↑*            *LY6K ↑*             *FUS ↑*              *DVL1 ↑*             *SLC4A1AP* ↕        *DERL3 ↓*          *MAL ↓*               
  -------------------- -------------------- ------------ -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- ------------------- ------------------ --------------------- ---------------------
  Pre invasive stage   Normal Oral Mucosa   32           0.849 (−0.02)        **0.015 (0.31)**     **0.05 (0.39)**      **\<0.001 (0.72)**   0.665 (0.58)         **\<0.001 (0.46)**   **0.018 (0.28)**    **0.001 (0.43)**   **\<0.001 (−0.48)**   **\<0.001 (−0.51)**
                       Leukoplakia          37                                                                                                                                                                                                      
  Invasive OSCC        Normal Oral Mucosa   32           **\<0.001 (0.31)**   **\<0.001 (0.27)**   **\<0.001 (0.45)**   **\<0.001 (0.42)**   **0.003 (0.23)**     **\<0.001 (0.27)**   0.620 (−0.03)       0.288 (0.08)       **\<0.001 (−0.31)**   **\<0.001 (−0.59)**
                       OSCC                 138                                                                                                                                                                                                     
  OSCC progression     Normal Oral Mucosa   32           **\<0.001 (0.39)**   **\<0.001 (0.35)**   **\<0.001 (0.68)**   **0.008 (0.19)**     **\<0.001 (0.36)**   0.141 (0.10)         **0.030 (−0.15)**   0.540 (−0.04)      **0.007 (−0.19)**     **\<0.001 (−0.68)**
                       Leukoplakia          37                                                                                                                                                                                                      
                       OSCC                 138                                                                                                                                                                                                     
  Tumor stage          Stage I/II           56           **0.044 (0.17)**     **\<0.001 (0.42)**   **\<0.001 (0.48)**   **0.041 (0.18)**     **0.001 (0.28)**     0.702 (0.03)         0.817 (0.09)        0.130 (0.21)       0.444 (−0.06)         **0.007 (−0.23)**
                       Stage III/IV         79                                                                                                                                                                                                      
  Tumor grade          Well                 12           0.181 (0.12)         0.250 (−0.10)        0.062 (0.16)         0.620 (0.04)         0.500 (0.06)         0.815 (0.02)         0.144 (−0.12)       0.980 (−0.02)      0.418 (0.07)          0.629 (−0.04)
                       Moderate             87                                                                                                                                                                                                      
                       Poor                 36                                                                                                                                                                                                      
  Node metastasis      Node negative        79           **0.018 (0.20)**     **0.015 (0.21)**     **\<0.001 (0.39)**   0.676 (0.03)         0.133 (0.13)         **0.029 (0.19)**     **0.014 (0.21)**    0.003 (0.25)       0.369 (0.08)          0.461 (−0.06)
                       Node positive        56                                                                                                                                                                                                      

coef\*: Spearman correlation coefficent. Bold font represents significant changes at a significance level of 0.05, ↑: up-regulated gene, ↓: down-regulated gene, ↕: unchanged gene; The association with OSCC progression was computed by comparing expression changes between leukoplakia, early stage OSCC and advance stage OSCC.

###### 

Representative Biological Processes Significantly Altered in Leukoplakia and OSCC.

Table 5

  GO:BP:ID        *P*-Value     Odds ratio    Count   Size   Biological process
  --------------- ------------- ------------- ------- ------ ----------------------------------------------------------
  Leukoplakia                                                
   GO:0044691     6.57E-05      433.0789474   2       3      tooth eruption
   GO:0035116     0.000373976   24.34222222   3       30     embryonic hindlimb morphogenesis
   GO:0021983     0.000879749   17.75243243   3       40     pituitary gland development
   GO:0030199     0.000879749   17.75243243   3       40     collagen fibril organization
   GO:0001568     0.001192229   3.794054527   9       556    blood vessel development
   GO:0071230     0.001591348   14.27130435   3       49     cellular response to amino acid stimulus
   GO:0043206     0.001656565   39.34688995   2       13     extracellular fibril organization
   GO:0040012     0.002562823   11.97495573   3       62     regulation of locomotion
   GO:0044259     0.002720644   7.421757892   4       123    multicellular organismal macromolecule metabolic process
   GO:0009888     0.002854111   2.692398599   13      1260   tissue development
                                                             
  OSCC                                                       
   GO:0008544     1.03E-09      5.089295677   24      307    epidermis development
   GO:2,000,145   1.90E-08      3.377582317   33      628    regulation of cell motility
   GO:0051674     3.78E-07      2.447114154   47      1237   localization of cell
   GO:0051272     4.34E-07      3.851913001   22      361    positive regulation of cellular component movement
   GO:0040017     6.57E-07      3.750171556   22      370    positive regulation of locomotion
   GO:0043207     1.47E-06      2.622472611   36      869    response to external biotic stimulus
   GO:0060337     2.07E-06      7.805019305   10      84     type I interferon signaling pathway
   GO:0034340     2.31E-06      7.70047619    10      85     response to type I interferon
   GO:0018149     5.56E-06      9.573286052   8       56     peptide cross-linking
   GO:0032496     8.14E-06      5.32031185    12      145    response to lipopolysaccharide

The top 10 dysregulated pathways (ordered by corrected *P*-value in Leukoplakia and OSCC), as identified by the Bioconductor package GOStats.

[^1]: These authors contributed equally to this work.
